This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Juvenile neuronal ceroid lipofuscinosis (JNCL) is a recessively inherited, progressive neurologic disease caused by mutations in the CLN3 gene, coding for a transmembrane protein with unknown function.1 The symptoms include visual failure, noticed around the age of 4 to 7 years, mental decline, epilepsy, parkinsonism, psychiatric symptoms, and sleeping difficulties. Thus far, no curative treatment is available and the disease leads to an early death at the age of 15 to 30 years.
Autoantibodies to glutamic acid decarboxylase 65 (GAD65) were detected in the sera of patients with JNCL and in CLN3 knock-out mice.2 As a biologic sign of these antibodies, decreased GAD65 activity and increased levels of glutamate were observed in the mice brains. Together these findings suggest that an immune-mediated reaction to GAD65 may be involved in the pathogenesis of JNCL.
Our aim was to test the effect of immunosuppressive therapy on the GAD65-antibodies, symptoms, and disease progression in patients with JNCL.
Methods.
Four girls and four boys with JNCL (table) were included in this 1-year study, approved by the Ethics Committee of the Hospital for Children and Adolescents, University of Helsinki.
- In this window
- In a new window
Table Patients, their GAD65-autoantibodies, verbal IQ, and weight for height ratio in percentage at the beginning (0 mo) and end …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
Dr. Kathleen Digre and Dr. Kendra Pham
► Watch
Alert Me
Recommended articles
Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms
Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease
Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores
A favorable response to antiparkinsonian treatment in juvenile neuronal ceroid lipofuscinosis